Literature DB >> 709548

Vindesine: a phase II study in the treatment of breast carcinoma, malignant melanoma, and other tumors.

I E Smith, D W Hedley, T J Powles, T J McElwain.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 709548

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


× No keyword cloud information.
  8 in total

Review 1.  Antineoplastic drugs in 1990. A review (Part II).

Authors:  D J Black; R B Livingston
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

2.  Combination chemotherapy with mitomycin C, vindesine and melphalan for refractory metastatic breast cancer.

Authors:  L Rausa; A Russo; V Gebbia; N Gebbia; N D'Alessandro; S Palmeri
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

3.  Phase II evaluation of vindesine in the treatment of colorectal and esophageal tumors.

Authors:  A Y Bedikian; M Valdivieso; G P Bodey; E J Freireich
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

4.  Establishment of Vincristine-resistant and vindesine-resistant lines of murine lymphoblasts in vitro and characterisation of their patterns of cross-resistance and drug sensitivities.

Authors:  B T Hill; R D Whelan
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

5.  Vindesine in advanced breast cancer, lymphoma and melanoma. A Colorado Clinical Oncology Group study.

Authors:  N J DiBella; R Berris; D Garfield; K Fink; J Speer; A Sakamoto
Journal:  Invest New Drugs       Date:  1984       Impact factor: 3.850

Review 6.  Chemotherapy of breast cancer.

Authors:  L S Perlow; J F Holland
Journal:  Med Oncol Tumor Pharmacother       Date:  1984

7.  Antitumor efficacy of seventeen anticancer drugs in human breast cancer xenograft (MX-1) transplanted in nude mice.

Authors:  K Inoue; S Fujimoto; M Ogawa
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

8.  Vindesine: phase II evaluation in colon cancer and description of its platelet stimulating activity.

Authors:  R Pazdur; A H Rossof; G Chandra; P D Bonomi; R E Slayton; J Wolter
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.